{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:25:07Z","timestamp":1788009907922,"version":"build-2784847793"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014125","name":"Fujian Provincial Health Commission","doi-asserted-by":"publisher","award":["2020CXA008"],"award-info":[{"award-number":["2020CXA008"]}],"id":[{"id":"10.13039\/501100014125","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background and objective<\/jats:title><jats:p>Whether sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NAC) for breast cancer is an alternative to axillary lymph node dissection (ALND) remains controversial. In this study, the results of SLNB performed with <jats:sup>99m<\/jats:sup>Tc-Rituximab combined with dyes were analyzed, and the application value of the double-tracing method of <jats:sup>99m<\/jats:sup>Tc-Rituximab combined with dyes in SLNB after breast cancer NAC was evaluated, the feasibility of SLNB after NAC and the clinical application of the novel tracer <jats:sup>99m<\/jats:sup>Tc-Rituximab and its value in internal mammary lymph node(IMLN) was discussed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis of 106 breast cancer patients who underwent post-NAC SLNB from August 2019 to August 2023 at Fujian Provincial Hospital, where SLNB was performed using <jats:sup>99m<\/jats:sup>Tc-Rituximab combined with dye imaging or dye imaging alone. The detection rate, sensitivity, false-negative rate, accuracy and the detection rate of internal mammary lymph node(IMLN) biopsy were compared between the two tracing methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>70 cases were included in the dual-tracer group, with a detection rate of 97.14% (68\/70), an average number of detected SLNs of (6.06 \u00b1 5.29), a sensitivity of 92.86% (26\/28), a false negative rate of 7.14% (2\/28), and an accuracy of 97.14% (68\/70). 36 cases were included in the single-tracer group, with a detection rate of 66.67% (24\/36), an average number of detected SLNs of (3.17 \u00b1 3.073), a sensitivity of 54.55% (11\/22), a false negative rate of 45.45% (10\/22), and an accuracy of 72.22% (26\/36). There were significant differences in the detection rate and the average number of detected SLNs between the two groups (detection rate: P=0.004; detection number: P=0.038), but there were no significant differences in the sensitivity, accuracy, and false negative rate (P&amp;gt;0.05). A total of 70 patients were examined for internal mammary lymph node biopsy with dual tracer, and 22 patients were detected with an imaging rate of 31.42% (22\/70), and a detection rate of 72.72% (16\/22).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>For patients with breast cancer, the dual-tracer method combining radionuclide and dye for SNLB after neoadjuvant chemotherapy can improve the detection rate of sentinel lymph nodes and reduce the false-negative rate. In the long term, the quality of life of patients can be helped to improve by this approach. Compared with other tracers, <jats:sup>99m<\/jats:sup>Tc-Rituximab can improve the detection rate of internal mammary lymph nodes, with the characteristics of rapid clearance of injection site, less secondary lymph node visualization, and hypoallergenicity, which can be used as an ideal tracer for further research.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1568550","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T05:31:54Z","timestamp":1754458314000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical study of 99mTc-Rituximab combined with dyes double tracing for axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Minxue","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HongBin","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HuanHong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengbo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.8369","article-title":"Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27","volume":"30","author":"Mamounas","year":"2012","journal-title":"JCO"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.1177","article-title":"Sentinel lymph node biopsy for patients with early-stage breast cancer: american society of clinical oncology clinical practice guideline update","volume":"32","author":"Lyman","year":"2014","journal-title":"JCO"},{"key":"B4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1001\/jamaoncol.2016.4163","article-title":"Axillary nodal management following neoadjuvant chemotherapy: A review","volume":"3","author":"Pilewskie","year":"2017","journal-title":"JAMA Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.160572","article-title":"Clinical evaluation of 99m tc-rituximab for sentinel lymph node mapping in breast cancer patients","volume":"57","author":"Li","year":"2016","journal-title":"J Nucl Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.7827","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study","volume":"33","author":"Boileau","year":"2015","journal-title":"JCO"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1001\/jamasurg.2018.2696","article-title":"Association of low nodal positivity rate among patients with ERBB2 -positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy","volume":"153","author":"Barron","year":"2018","journal-title":"JAMA Surg"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-5004-7","article-title":"Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study","volume":"173","author":"Classe","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.19538\/j.cjps.issn1005-2208.2021.11.08","article-title":"Principles of sentinel lymph node management in neoadjuvant therapy for breast cancer","volume":"41","author":"Yu","year":"2021","journal-title":"Chin J Pract Surgery"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6345-5","article-title":"A predictive model for axillary node pathologic complete response after neoadjuvant chemotherapy for breast cancer","volume":"25","author":"Kantor","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.19401\/j.cnki.1007-3639.2019.06.008","article-title":"Validation and modification study of axillary node pathologic complete response predictive model after neoadjuvant chemotherapy for breast cancer","volume":"29","author":"Zheng","year":"2019","journal-title":"China Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jamaoncol.2023.3759","article-title":"Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial","volume":"9","author":"Gentilini","year":"2023","journal-title":"JAMA Oncol"},{"key":"B16","article-title":"Prevention of lymphedema of upper limb by axillary reverse mapping","volume":"8","author":"Yue","year":"2014","journal-title":"Chin J Breast Disease(Electronic Edition)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09211-0","article-title":"Oncologic safety of sentinel lymph node biopsy alone after neoadjuvant chemotherapy for breast cancer","volume":"28","author":"Wong","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.breast.2021.09.004","article-title":"Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23\/16, IBCSG 57-18, ABCSG-53, GBG 101)","volume":"60","author":"Weber","year":"2021","journal-title":"Breast"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9610(01)00734-6","article-title":"Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer","volume":"182","author":"Albo","year":"2001","journal-title":"Am J Surg"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3877\/cma.j.issn.1674-0807.2017.04.001","article-title":"Guide for fluorescence tracer sentinel lymph node biopsy in breast cancer","volume":"11","year":"2017","journal-title":"Chin J Breast Dis"},{"key":"B21","article-title":"Advance in sentinel lymph node biopsy with breast cancer. Master","author":"Chen","year":"2014"},{"key":"B22","article-title":"The biology of CD20 and its potential as a target for mAb therapy","volume-title":"Current Directions in Autoimmunity","author":"Cragg","year":"2004"},{"key":"B23","volume-title":"The Preliminary Analysis of Sentinel Lymph Node Biopsy Guided by 99mTc-Rituximab in Patients with Breast Cancer","author":"Zhang","year":"2018"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4591-z","article-title":"99mTc-rituximab as a tracer for sentinel lymph node biopsy in breast cancer patients: a single-center analysis","volume":"168","author":"Wang","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"B25","doi-asserted-by":"publisher","first-page":"442","DOI":"10.4048\/jbc.2018.21.e49","article-title":"Internal mammary sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer","volume":"21","author":"Bi","year":"2018","journal-title":"J Breast Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1100077","article-title":"99mTc-rituximab tracer injection for guiding internal mammary sentinel lymph nodes biopsy in primary breast cancer: A prospective observational study","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.21037\/gs.2016.09.11","article-title":"Anatomical basis of pedicles in breast reduction","volume":"6","author":"Irigo","year":"2017","journal-title":"Gland Surg"},{"key":"B28","first-page":"944","volume-title":"Tumor of the breast","author":"Shao","year":"2013"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1568550\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T05:31:58Z","timestamp":1754458318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1568550\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":28,"alternative-id":["10.3389\/fonc.2025.1568550"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1568550","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"article-number":"1568550"}}